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Benefit and harm associated with treating actinic keratosis (AK) with the immune response modifier imiquimod
was assessed using published randomized-controlled trials. Five randomized double-blind trials lasted 12–16
weeks and treated 1,293 patients. Complete clearance occurred in 50% of patients treated with imiquimod,
compared to 5% treated with vehicle, and the number needed to treat (NNT) for one patient to have their
keratosis completely cleared after 12–16 weeks was 2.2 (95% confidence interval 2.0–2.5). For partial (X75%)
clearance the NNT was 1.8 (1.7–2.0). The proportion of patients with any adverse event, any local adverse event,
or any treatment-related adverse event was substantially higher with imiquimod than with vehicle, and numbers
needed to harm for one additional adverse event with imiquimod over 12–16 weeks ranged from 3.2 to 5.9.
Particular local adverse events with imiquimod included erythema (27%), scabbing or crusting (21%), flaking
(9%), erosion (6%), edema (4%), and weeping (3%). Imiquimod 5% cream was effective in the treatment of AK,
preventing potential development of squamous cell carcinoma. Future investigation might be aimed at
elucidating optimal dosing to minimize adverse events without detriment to efficacy, and evaluating long-term
recurrence.
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INTRODUCTION
Actinic keratosis (AK; solar keratosis or squamous cell
carcinoma in situ), is a localized area of dysplasia with
malignant potential and regarded as a strong predictor of a
subsequent squamous cell carcinoma (Memon et al., 2000).
Estimates of progression of AK to invasive squamous cell
carcinoma range fromo1 to 16% (Persaud et al., 2002). It is
impossible to predict the point at which an individual AK
lesion will evolve into invasive squamous cell carcinoma, so
most clinicians advocate the treatment of all AK lesions
(Lebwohl et al., 2004). Squamous cell carcinoma of the skin
has potential to metastasize and may account for up to 20%
of deaths from skin cancer (Szeimies et al., 2004).
Most AKs are diagnosed clinically (red, scaly papules or
plaques, 2–5 mm in diameter, occurring in sun-exposed sites
such as face, ears, neck, forearms, hands, and balding scalp)
and rarely confirmed histologically. A positive predictive
value of 74% for diagnosis of AK suggests that the threshold
for biopsy of suspect lesions in patients with a history of skin
cancer should be low and warrant further evaluation (Venna
et al., 2005).
AK development is associated with individual suscept-
ibility (i.e. fairness of skin), cumulative ultraviolet radiation
exposure and advancing age (Perras, 2004). Although the
highest incidence is reported in Australia (40–60% in white-
skinned adults; Lebwohl et al., 2004), a recent study in
England demonstrated that sun exposure received in ‘‘nor-
mal’’ life is sufficient for potentially malignant skin damage in
a significant proportion of the population (Memon et al.,
2000).
Current treatment of AK involves surgical or non-surgical
interventions or a combination. Cryosurgery and curettage
are used for small areas with few lesions. Other treatment
options include chemical peels, dermabrasion, laser therapy,
excision, and photodynamic therapy (Perras, 2004), as well
as retinoid therapy and intralesional interferon. Currently,
prescribed therapies can be painful and may result in scarring
and changes in skin pigmentation (Stockfleth et al., 2004). A
recent meta-analysis of three randomized trials of topical
diclofenac with sodium hyaluronate (Pirad et al., 2005)
reported the outcome of complete resolution of all lesions 30
days after the end of treatment in 39% of patients, with a
number needed to treat (NNT) of 3.7 (95% confidence
interval 2.8–5.5). Another review reported the same outcome
with 5-fluorouracil in 53% of patients, with an indicated NNT
of about 2 (Jorizzo, 2005). Direct comparisons between them
are not available, and indirect comparison is limited by few
trials and patients.
Imiquimod 5% cream has been available since 1997 for
the treatment of genital and perianal warts (Moore et al.,
2001). Imiquimod, an imidazoquinoline amine, is an
immune-response modifier that stimulates both innate and
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adaptive arms of the immune system (Sauder, 2003). This
novel therapy therefore targets a critical component that
current therapies do not: the suppression of the immune
response (Lober and Fenske, 2004; Korman et al., 2005).
Differences in gene expression between AK and uninvolved
skin have been demonstrated, and recent evidence suggests
that imiquimod causes pharmacological modulation of
expression in this context (Lysa et al., 2004). Treatment with
75 mg three times per week for 16 weeks demonstrated
minimal systemic absorption and good safety margins for
topical administration (Harrison et al., 2004), although
adverse effects include headaches, influenza-like symptoms,
and myalgia.
This is the first meta-analysis of short-term randomized-
controlled trials evaluating the efficacy and safety of
imiquimod 5% cream for the treatment of AK.
RESULTS
Literature searches identified 19 publications, 14 of which
were excluded (Table S1) and five included (details in Table
S2). Of 1,293 included patients, almost 90% were men. The
mean age ranged from 64 to 71 years, with individual
patients aged from 37 to 94 years. More patients had
Fitzpatrick skin types I and II, but individuals with types
I–IV were included. All studies diagnosed AK by clinical
examination, supplemented by biopsy and histology in two
trials (Stockfleth et al., 2004; Szeimies et al., 2004).
Two studies (Stockfleth et al., 2004; Chen et al., 2003)
were small, with about 40 patients, while the other three
(Lebwohl et al., 2004; Szeimies et al., 2004; Korman et al.,
2005) each had 280–500 patients. Trial duration was 12–16
weeks. Quality scores were high; all trials reported being
both randomized and double blind, scoring 3 or more of the
maximum 5 points. All five trials used one sachet of 5%
imiquimod cream or vehicle cream (placebo) twice or three
times a week; none used an active control. Cream was
applied to specified areas of sun-exposed skin, usually
20–25 cm2 on the face and balding scalp, but including
neck, forearms, and hand in one trial (Stockfleth et al., 2004).
All trials were conducted in the setting of home administra-
tion after initial professional examination and advice.
Complete clearance occurred in 50% of patients with
imiquimod, compared with 5% with vehicle (Figure 1;
Table 1). The NNT for one patient to have keratoses
completely cleared after 12–16 weeks was 2.2 (95%
confidence interval 2.0–2.5). For partial clearance the NNT
was 1.8 (1.7–2.0) (Figure 1; Table 1). For both complete and
partial clearance, results were consistent between individual
trials. NNTs for the three trials reporting formal lesion-
counting methods were lower (better) than for all trials
combined (Table 1).
Adverse event information was available on over 1,200
patients. The proportion of patients with any adverse event,
local adverse event, or treatment-related adverse event was
substantially higher with imiquimod than with vehicle
(Table 1), and number needed to harm to produce one
additional adverse event with imiquimod over 12–16 weeks
ranged from 3.2 to 5.9. Serious adverse events were not
significantly different between imiquimod or vehicle control,
with a relative risk of 1.2 (0.7–2.0).
Most adverse events were local, most frequently erythema,
scabbing, and flaking. Figure 2 shows the percentage of
patients reporting each of a number of local adverse events
with imiquimod. All of these, apart from vesicles, occurred
significantly more frequently with imiquimod than with
vehicle.
All-cause withdrawals occurred about twice as frequently
with imiquimod than with vehicle (Table 1), with an NNT to
cause one additional withdrawal of 20 (12–55). Withdrawals
due to adverse events were not significantly different between
imiquimod and vehicle, with a relative risk of 1.5 (0.8–2.7).
There were no data concerning withdrawals due to lack of
efficacy.
DISCUSSION
This systematic review is the first comparison of randomized-
controlled trials for the use of imiquimod 5% cream in the
treatment of AK. The five trials, with 1,293 patients were of
high reporting quality minimizing the risk of bias, and were
valid, involving patients with multiple lesions, using home
application to mimic clinical practice, and of sufficient
duration to measure both benefits and harm, though not
recurrence.
There were limitations, however. Two of the five studies
used histological rather than clinical diagnoses of AK.
Although histology has a positive predictive value of 74%
for the diagnosis of AK (Venna et al., 2005), in practice
clinical rather than histological diagnosis is likely. Studies
were clinically homogeneous, with 97% of patients having
ketatoses on the face and balding scalp only; one small study
(Stockfleth et al., 2004) recruited some patients with lesions
on thicker skin of neck or forearms. The reliability of using AK
lesion counts as an outcome has been questioned (Weinstock
et al., 2001). Studies dealt with this potential problem by
using photographs or diagrams and the same investigator
counting lesions (Stockfleth et al., 2004; Chen et al., 2003)
and one (Szeimies et al., 2004) favorably compared clinical
counting with histology, and had lower, better, NNTs than
those that did not report using these methods (Table 1).
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Figure 1. Complete and partial clearance with imiquimod and vehicle in
individual trials at 12–16 weeks. Each symbol represents a single trial, and the
size of trial is shown in the inset scale. The diagonal line shows the line of
equivalence between imiquimod and vehicle.
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The NNT of 2.2 (2.0–2.5) for complete clearance of AK
lesions, and 1.8 (1.7–2.0) for partial clearance, shows that
imiquimod 5% cream is an effective therapy, at least in the
short term. This compares with NNTs of 3.7 and 2.0 for
topical diclofenac and 5-fluorouracil for complete clearance
about 4 weeks after the end of treatment.
Although treatment with imiquimod cream is associated
with adverse events, particularly local skin reactions, this
could be deemed important in arriving at the optimal
efficacy. Better clearance was seen in subjects with the most
severe adverse events (Stockfleth et al., 2004). Chen et al.
(2003), found that better clearance occurred in subjects with
larger increases in AK lesions during initial therapy, and
Korman et al. (2005), found that both an increase in the
number of lesions and intensity of local skin reaction was
associated with better clearance rates.
Optimal frequency and duration of treatment remain to be
determined. A small open-label trial in 25 subjects evaluated
cycle therapy using 5% imiquimod cream, suggesting that
alternative dosing regimens may reduce adverse effects
(Salasche et al., 2002).
Long-term effectiveness was addressed by only one study
in this review (Stockfleth et al., 2004). Twenty-four of 27
patients randomized to imiquimod (three applications per
week) were reviewed 1 year after final application, and
clinical recurrence was found in two, giving a recurrence rate
of about 10%. One further study (Lee et al., 2005) followed
up patients with complete clearance from four Phase III
studies, after a median of 16 months, in which 82% of
eligible patients underwent clinical examination. Recurrence
occurred in 19/77 (25%) of those treated with imiquimod
three times per week, 23/54 (43%) of those treated twice a
week, and 7/15 (47%) treated with vehicle cream. No
clinically meaningful long-term adverse events were re-
ported, and skin quality in the treated area showed no
long-term adverse changes.
Table 1. Results for clearance of keratosis, withdrawals, and adverse events
Number of Percent with Relative benefit/risk NNT
Outcome Trials Patients Imiquimod Vehicle (95% confidence interval) (95% confidence interval)
Clearance
Complete 5 1,293 50 4.7 11 (7.4–15) 2.2 (2.0–2.5)
Partial (475%) 5 1,293 65 11 5.9 (4.7–7.4) 1.8 (1.7–2.0)
Clearance (formalized lesion counts)
Complete 3 365 56 2.8 19 (7.8–46) 1.9 (1.7–2.2)
Partial 3 365 74 5.9 11 (6.3–21) 1.5 (1.3–1.7)
Withdrawals NNH
All-cause 4 1,254 12 6.6 1.7 (1.2–2.5) 20 (12–55)
Adverse event 5 1,291 3.9 2.7 1.5 (0.8–2.7)
Adverse events NNH
Any 4 1,250 75 58 1.3 (1.2–1.4) 5.9 (4.5–8.5)
Local 5 1,289 43 12 3.5 (2.8–4.4) 3.2 (2.8–3.7)
Treatment related 3 1,214 42 12 3.5 (2.8–4.4) 3.3 (2.9–3.9))
Serious 3 1,214 4.5 3.8 1.2 (0.7–2.0)
Specific adverse events NNH
Erythema 3 1,212 27 1.1 25 (12–55) 3.9 (3.4–4.5)
Scabbing 3 1,212 21 1.1 20 (9–43) 5.0 (4.3–6.0)
Flaking 3 1,214 8.6 1.6 5.2 (2.7–10) 14 (11–22)
Erosion 2 722 5.7 0.3 13 (2.5–69) 19 (13–36)
Edema 2 722 3.9 0.0 14 (1.8–100) 28 (18–65)
Weeping 2 722 3.2 0.0 11 (1.4–87) 35 (21–99)
Vesicles 2 722 0.3 0.0
NNT is the number of patients needed to be treated with imiquimod rather than vehicle to obtain one additional beneficial event. NNH is the number of
patients needed to be treated with imiquimod rather than vehicle to obtain one additional harmful event.
Erythema
Scabbing/crusting
Flaking/scaling/dryness
Erosion/ulceration
Edema
Weeping/exudate
Vesicles
0 10 20 30
Percent with severe local skin reactions
Figure 2. Percentage of imiquimod-treated patients reporting particular
severe local adverse events.
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This review demonstrates the effective use of imiquimod
5% cream in the short-term treatment of AK. Future
investigations should be aimed at elucidating optimal dosing
regimens to minimize adverse events without detriment to
efficacy, and outcomes beyond 16 weeks are also needed.
MATERIALS AND METHODS
QUORUM guidelines were followed (Moher et al., 1999). Full
journal publications in any language of randomized trials of
imiquimod for AK were sought. Eligible reports were identified from
MEDLINE (to August 2005), Cochrane Library (Issue 2, 2005), and
PubMed (to August 2005), using the terms: (imiquimod or aldara)
and ((actinic or solar) and keratosis) and (random OR randomized).
Review articles (Lober and Fenske, 2004; Perras, 2004) and
reference lists were also used. The manufacturers of AldaraTM
(imiquimod 5% cream; 3 M, Loughborough, Leicestershire, UK) were
asked about any published or unpublished trials. Authors were not
contacted regarding unpublished reports or additional information
from published reports.
Included were full publications of randomized double-blind trials
investigating imiquimod for AK with efficacy or safety data. Excluded
were reviews with clinical information published elsewhere,
biochemical or immunological studies, abstracts, and studies in
conditions other than AK.
Each report was scored for quality using a three-item quality scale
(Jadad et al., 1996). A maximum of five points were awarded to
studies according to whether they were randomized, double blind,
and accounted for withdrawals or drop-outs, and whether the
methods of randomization and double blinding were described and
appropriate.
Information was extracted independently by two reviewers
(G.H., S.D.), and checked by the third (R.A.M.). From each trial
we extracted the number of patients treated per group, dosing
regimes, study design (including the rigor of lesion-counting
methods, such as use of photography, and a single assessor), and
the number of patients with efficacy and/or safety outcomes. Three
main efficacy outcomes and five harm outcomes were sought from
the trials, using as denominator the number of patients randomized,
so that results were on an intention-to-treat basis. They were:
K Complete clearance of lesions in the treatment area.
K Partial clearance; at least 75% reduction in the number of
lesions in the treatment area.
K Complete clearance of AK and no recurrence thereafter.
K Patients withdrawing for any cause.
K Patients withdrawing from the study because of treat-
ment-related adverse effects.
K Patients withdrawing from the study because of lack of
efficacy.
K Patients with at least one adverse event.
K Patients with serious, treatment-related, and particular
local or systemic adverse effects.
Relative benefit and risk estimates were calculated with 95%
confidence intervals using a fixed effects model (Morris and
Gardner, 1995). Heterogeneity tests were not used as they have
previously been shown to be unhelpful (Gavaghan et al., 2000).
Publication bias was not assessed using funnel plots as these tests
have been shown to be unhelpful (Sterne et al., 2000; Terrin et al.,
2005); homogeneity was assessed visually (L’Abbe et al., 1987). The
NNT and number needed to harm with confidence intervals were
calculated by the method of Cook and Sackett (1995). Relative
benefit or risk was considered to be statistically significant when the
95% confidence interval did not include 1. NNT or number needed
to harm values were only calculated when the relative risk or benefit
was statistically significant, and are reported with the 95%
confidence interval.
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